The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

Brian Ongioni, chief product officer, uMotif, discusses how AI and machine learning can enhance patient-reported outcomes by ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Brian Ongioni, chief product officer, uMotif, explains how early patient feedback plays a crucial role in shaping digital ...

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

As clinical research increasingly relies on RWD to enhance trial design and patient insights, tokenization has emerged as a ...

Cashin, MD, chief medical officer, Novotech, emphasizes the importance of proactive communication, strategic alignment, and ...

Cashin, MD, chief medical officer, Novotech, explores how CRO partnerships are shifting to deliver greater efficiency, cost-effectiveness, and regulatory insight in response to tightening budgets and ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...